Evidence map›Paper›PMID 42293378›Full record

ArticleMaterials today. Bio2026

A tetrahedral framework DNA-based bioswitchable miR-26a-5p delivery system for idiopathic pulmonary fibrosis.

Ziwei Lei, Cheng Chen, Jiajie Shi, Zong Shen, Ping Ling, Chenru Wei, Banghui Zhu, Weishi Kong, Zhibin Zhang, Tianyu Chen and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Ziwei LeiDepartment of Burn Surgery, The First Affiliated Hospital, Naval Medical University, Shanghai, 200433, China.
Cheng ChenDepartment of Respiratory and Critical Care Medicine, Shanghai Changzheng Hospital, The Second Affiliated Hospital of Naval Medical University, Shanghai, 200003, China.
Jiajie ShiDepartment of Respiratory and Critical Care Medicine, Shanghai Changzheng Hospital, The Second Affiliated Hospital of Naval Medical University, Shanghai, 200003, China.
Zong ShenDepartment of Burn Surgery, The First Affiliated Hospital, Naval Medical University, Shanghai, 200433, China.
Ping LingDepartment of Burn Surgery, The First Affiliated Hospital, Naval Medical University, Shanghai, 200433, China.
Chenru WeiDepartment of Burn Surgery, The First Affiliated Hospital, Naval Medical University, Shanghai, 200433, China.
Banghui ZhuDepartment of Burn Surgery, The First Affiliated Hospital, Naval Medical University, Shanghai, 200433, China.
Weishi KongDepartment of Burn Surgery, The First Affiliated Hospital, Naval Medical University, Shanghai, 200433, China.
Zhibin ZhangDepartment of Burn Surgery, The First Affiliated Hospital, Naval Medical University, Shanghai, 200433, China.
Tianyu ChenChengdu Yun Hai Tetrahedron Biotech Co. Ltd, Chengdu, 610041, China.
Bing XiangChengdu Yun Hai Tetrahedron Biotech Co. Ltd, Chengdu, 610041, China.
Hongyi HeChengdu Yun Hai Tetrahedron Biotech Co. Ltd, Chengdu, 610041, China.
Hao TangDepartment of Respiratory and Critical Care Medicine, Shanghai Changzheng Hospital, The Second Affiliated Hospital of Naval Medical University, Shanghai, 200003, China.
Xiaoyan ZhuDepartment of Physiology, Naval Medical University, Shanghai, 200433, China.
Yu SunDepartment of Burn Surgery, The First Affiliated Hospital, Naval Medical University, Shanghai, 200433, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal interstitial lung disease with severely limited therapeutic options. MicroRNAs, especially miR-26a-5p, have exhibited potent anti-fibrotic effects in preclinical studies. However, their clinical translation has been impeded by intrinsic susceptibility to enzymatic degradation in physiological environments and poor cellular internalization efficiency. In this study, we developed a tetrahedral framework nucleic acid-based bioswitchable miRNA delivery system, termed BiRDS26, for the targeted delivery of miR-26a-5p. BiRDS26 demonstrated robust anti-fibrotic activity in both in vitro and in vivo models, mechanistically mediated by the coordinated suppression of the Hippo and Wnt signaling pathways. Collectively, these results position BiRDS26 as a rationally engineered nanotherapeutic platform with significant translational potential for IPF treatment.

Indexed as

Bioswitchable miRNA delivery systemEMTGene deliveryLung fibrosismiRNATetrahedral framework nucleic acids

Identifiers

PMID42293378
PMCPMC13253135

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.